Delivery Order 75N93018D00011-75N93024F00001
Award Date 5/15/18
Potential Completion Date 4/18/25
Potential Value $9.3M
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Potomac, MD 20850, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
3
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a fixed-price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to IDT Biologika GMBH, a German biotechnology company. The contract is for the manufacturing of master cell banks to support COVID-19 pandemic preparedness efforts. The base award is for $20,462.00, with a total potential ceiling value of $554,341.00. The contract has an ultimate completion date of May 17, 2025,...
- This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to IDT Biologika GMBH, a foreign-owned, for-profit biotechnology company based in Germany. The contract is a $70,108.14 delivery order under a larger indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle for manufacturing and characterization services for vaccines and other biologics for infectious diseases. The...
- This is a federal delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to IDT Biologika GMBH, a foreign-owned, for-profit biotechnology company based in Germany. The contract, valued at a ceiling of $2,723,700.00, is for vaccine manufacturing and characterization services to support infectious disease research and pandemic preparedness efforts. Specific work includes the development,...
- This is a federal contract award made by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services. The $555,600.00 contract was awarded to IDT Biologika GMBH, a German biotechnology company, for the development and manufacture of toxoid fusion proteins and master cell banks. The contract has a total ceiling value of $1,693,261.00 and is a delivery order with a...
- This is a firm fixed-price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to IDT Biologika GMBH, a German biotechnology company. The $1,366,000 contract is for the development, manufacturing, and characterization of various biological materials to support infectious disease research and pandemic preparedness efforts, including influenza virus human challenge material, Staphylococcus aureus...
- This is a prime contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS), to IDT Biologika GMBH, a German biotechnology company. The $1,149,011.00 firm fixed price contract is for process development and master bank production of a Staphylococcus aureus protein A product. This work supports NIAID's infectious disease research and pandemic preparedness...
- This is a $24,295,876.00 delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to IDT Biologika GMBH, a German biotechnology company. The contract is for the manufacture of influenza virus human challenge material to support Phase 1 and 2 clinical trials. This work is likely part of NIAID's broader infectious disease research and pandemic preparedness efforts. The contract...
- This is a federal contract award made by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Integrated DNA Technologies, Inc. (IDT). The contract is a Blanket Purchase Agreement (BPA) valued at up to $100,000,000 with a period of performance through August 31, 2025. It allows for the delivery of various biological, oligonucleotide synthesis, and related laboratory supplies and services to support multiple federal...
- This federal contract award, valued at $76,175.52, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract was awarded to Sartorius Corporation, a subsidiary of the German company Sartorius Aktiengesellschaft, to provide biosensors and associated products and services. The original solicitation was a simplified acquisition request for quotes to support the Vaccine Research Center's...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $31,202.00 fixed-price level of effort contract is for process development of vaccine candidates, including for SARS-CoV-2. The award has an ultimate completion date of April 15, 2025. ABL has been awarded multiple indefinite...
- 75N93018D00011Indefinite Delivery Contract
- 75N93018D00011-75N93024F00001Delivery Order
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to IDT Biologika GMBH, a German biotechnology company. The contract, valued at $9,317,000.00, is for the manufacturing of master cell banks for next-generation SARS-CoV-2 vaccines as part of pandemic preparedness efforts. The contract is a delivery order with a firm fixed-price pricing structure and has an ultimate completion date of April 18, 2025. IDT Biologika GMBH is a foreign-owned, for-profit organization that specializes in contract manufacturing of vaccines, viral vectors, and other biologics. This award is not associated with a set-aside designation.
Generated 5/2/25, 10:21 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Terminate for Convenience | $0 | 4/22/25 | |
| P00001 | Exercise an Option | $1.7m | 4/26/24 | |
| Not listed | Not listed | $944.9k | 3/25/24 |